Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1CNS 1Breast 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 15Neoplasms 10Carcinoma, Renal Cell 8Carcinoma, Hepatocellular 8Melanoma 7Carcinoma, Non-Small-Cell Lung 7Endometrial Neoplasms 6Thyroid Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Thyroid Cancer, Papillary 3Stomach Neoplasms 3Neuroendocrine Tumors 3Colorectal Neoplasms 3Adenocarcinoma, Follicular 3Ovarian Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoma 2Lung Neoplasms 2Glioma 2Carcinoma, Transitional Cell 2Carcinoma 2Biliary Tract Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1

Interventions

Oxaliplatin 53Cisplatin 52Fluorouracil 50Capecitabine 48pembrolizumab 39Leucovorin 31Docetaxel 26Trastuzumab 23Paclitaxel 20Irinotecan 20Ramucirumab 13Bevacizumab 12Cetuximab 9Radiotherapy 8Surgical Procedures, Operative 7S 1 (combination) 7Nivolumab 7Epirubicin 7Carboplatin 6olaparib 5Platinum 5Everolimus 5Sunitinib 4Mitomycin 4trastuzumab deruxtecan 3lenvatinib 3epacadostat 3bemarituzumab 3apatinib 3Saline Solution 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Stomach Neoplasms × lenvatinib × Clear all
NCT03797326 2026-05-04

LEAP-005

Merck Sharp & Dohme LLC

Phase 2 Completed
611 enrolled 27 charts
BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03609359 2025-04-16

Lenva+Pembro

National Cancer Center Hospital East

Phase 2 Completed
29 enrolled 20 charts
Gastrointestinal

Stomach Neoplasms

NCT03321630 2024-03-27

A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies

NYU Langone Health

Phase 2 Completed
24 enrolled 10 charts
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡